Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""gp41"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 2154
Tytuł:
Impact of stabilizing mutations on the antigenic profile and glycosylation of membrane-expressed HIV-1 envelope glycoprotein.
Autorzy:
Tong T; San Diego Biomedical Research Institute, San Diego, California, United States of America.
D'Addabbo A; School of Biological Sciences, University of Southampton, Southampton, United Kingdom.
Xu J; San Diego Biomedical Research Institute, San Diego, California, United States of America.
Chawla H; School of Biological Sciences, University of Southampton, Southampton, United Kingdom.
Nguyen A; San Diego Biomedical Research Institute, San Diego, California, United States of America.
Ochoa P; San Diego Biomedical Research Institute, San Diego, California, United States of America.
Crispin M; School of Biological Sciences, University of Southampton, Southampton, United Kingdom.
Binley JM; San Diego Biomedical Research Institute, San Diego, California, United States of America.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2023 Aug 07; Vol. 19 (8), pp. e1011452. Date of Electronic Publication: 2023 Aug 07 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
HIV Envelope Protein gp41*/genetics
HIV Envelope Protein gp41*/metabolism
HIV-1*
Humans ; Glycosylation ; Mannose/metabolism ; Mutation ; Glycoproteins/metabolism ; HIV Envelope Protein gp120/genetics ; HIV Envelope Protein gp120/metabolism ; HIV Antibodies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Asymmetric conformations of cleaved HIV-1 envelope glycoprotein trimers in styrene-maleic acid lipid nanoparticles.
Autorzy:
Wang K; State Key Laboratory for Mesoscopic Physics, School of Physics, Peking University, Beijing, China.; Peking-Tsinghua Joint Center for Life Science, Peking University, Beijing, China.
Zhang S; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Microbiology, Harvard Medical School, Boston, MA, USA.
Go EP; Department of Chemistry, University of Kansas, Lawrence, KS, USA.
Ding H; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Wang WL; State Key Laboratory for Mesoscopic Physics, School of Physics, Peking University, Beijing, China.
Nguyen HT; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Microbiology, Harvard Medical School, Boston, MA, USA.
Kappes JC; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.; Birmingham Veterans Affairs Medical Center, Research Service, Birmingham, AL, USA.
Desaire H; Department of Chemistry, University of Kansas, Lawrence, KS, USA.
Sodroski J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. joseph_.; Department of Microbiology, Harvard Medical School, Boston, MA, USA. joseph_.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA. joseph_.
Mao Y; State Key Laboratory for Mesoscopic Physics, School of Physics, Peking University, Beijing, China. .; Peking-Tsinghua Joint Center for Life Science, Peking University, Beijing, China. .; Center for Quantitative Biology, Academy of Advanced Interdisciplinary Studies, Peking University, Beijing, China. .; National Biomedical Imaging Center, Peking University, Beijing, China. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2023 May 18; Vol. 6 (1), pp. 535. Date of Electronic Publication: 2023 May 18.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Envelope Protein gp41*/chemistry
HIV Envelope Protein gp41*/metabolism
HIV-1*/chemistry
Humans ; Protein Conformation ; Glycoproteins ; Styrenes
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Molecular Dynamics Investigation of Lipid-Specific Interactions with a Fusion Peptide.
Autorzy:
Heller WT; Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2024 Feb 27; Vol. 14 (3). Date of Electronic Publication: 2024 Feb 27.
Typ publikacji:
Journal Article
MeSH Terms:
Lipid Bilayers*/chemistry
HIV-1*/metabolism
Molecular Dynamics Simulation ; HIV Envelope Protein gp41/chemistry ; Peptides/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The TZM-bl Reporter Cell Line Expresses Kynureninase That Can Neutralize 2F5-like Antibodies in the HIV-1 Neutralization Assay.
Autorzy:
Morozov V; Institute of Human Virology, University of Maryland, Baltimore, MD 21201, USA.; Department of Infectious Diseases, Robert Koch Institute, 13353 Berlin, Germany.
Lagaye S; Centre de Recherche Saint-Antoine (CRSA), INSERM-UMR-S 938/Sorbonne Université, CEDEX 12, 75571 Paris, France.
Morozov A; Laboratory of Regulation of Intracellular Proteolysis, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Jan 07; Vol. 23 (2). Date of Electronic Publication: 2022 Jan 07.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal/*metabolism
Antibodies, Neutralizing/*metabolism
Broadly Neutralizing Antibodies/*metabolism
HIV Antibodies/*metabolism
HIV Envelope Protein gp41/*immunology
HIV-1/*immunology
Hydrolases/*metabolism
Animals ; Chlorocebus aethiops ; Epitopes/immunology ; HEK293 Cells ; HIV Envelope Protein gp41/chemistry ; HeLa Cells ; Hep G2 Cells ; Humans ; Hydrolases/chemistry ; Hydrolases/genetics ; Jurkat Cells ; Neutralization Tests ; Protein Domains ; Vero Cells
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
HIV-1 Envelope Conformation, Allostery, and Dynamics.
Autorzy:
Bennett AL; Duke Human Vaccine Institute, Durham, NC 27710, USA.
Henderson R; Duke Human Vaccine Institute, Durham, NC 27710, USA.; Department of Medicine, Duke University, Durham, NC 27710, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 May 07; Vol. 13 (5). Date of Electronic Publication: 2021 May 07.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms:
HIV Envelope Protein gp41/*chemistry
HIV-1/*genetics
env Gene Products, Human Immunodeficiency Virus/*chemistry
env Gene Products, Human Immunodeficiency Virus/*metabolism
Antibodies, Neutralizing/immunology ; HIV Antibodies/immunology ; HIV Envelope Protein gp41/genetics ; HIV Envelope Protein gp41/immunology ; HIV-1/chemistry ; HIV-1/immunology ; Models, Molecular ; Protein Binding ; Protein Conformation ; Protein Multimerization ; Virus Internalization ; env Gene Products, Human Immunodeficiency Virus/genetics ; env Gene Products, Human Immunodeficiency Virus/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Thermostable chaperone-based polypeptide biosynthesis: Enfuvirtide model product quality and protocol-related impurities.
Autorzy:
Zenin V; Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russian Federation.
Tsedilin A; Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russian Federation.
Yurkova M; Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russian Federation.
Siniavin A; Ivanovsky Institute of Virology, N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russian Federation.
Fedorov A; Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russian Federation.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Jun 08; Vol. 18 (6), pp. e0286752. Date of Electronic Publication: 2023 Jun 08 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections*/drug therapy
HIV Fusion Inhibitors*/pharmacology
Humans ; Enfuvirtide/pharmacology ; Peptide Fragments/chemistry ; HIV Envelope Protein gp41/chemistry ; Peptides/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies.
Autorzy:
Xu L; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Wang C; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Xu W; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Xing L; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Zhou J; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Pu J; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Fu M; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Lu L; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Jiang S; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Wang Q; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jun 05; Vol. 24 (11). Date of Electronic Publication: 2023 Jun 05.
Typ publikacji:
Journal Article
MeSH Terms:
HIV-1*
COVID-19*
HIV Infections*
HIV Fusion Inhibitors*/pharmacology
Humans ; Lipopeptides/pharmacology ; SARS-CoV-2 ; Anti-Retroviral Agents ; HIV Envelope Protein gp41
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform-Analysis of Production and Immunogenicity.
Autorzy:
Ortiz R; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.; Doctorate School, Microbiology Department, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Barajas A; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.; Doctorate School, Medicine Department, University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Spain.
Pons-Grífols A; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.; Doctorate School, Microbiology Department, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Trinité B; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.
Tarrés-Freixas F; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.
Rovirosa C; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.
Urrea V; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.
Barreiro A; HIPRA, 17170 Amer, Spain.
Gonzalez-Tendero A; HIPRA, 17170 Amer, Spain.
Cardona M; HIPRA, 17170 Amer, Spain.
Ferrer L; HIPRA, 17170 Amer, Spain.
Clotet B; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.; Doctorate School, Medicine Department, University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Spain.; Infectious Diseases Department, Germans Trias I Pujol Hospital, 08916 Badalona, Spain.
Carrillo J; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.; CIBERINFEC, ISCIII, 28029 Madrid, Spain.
Aguilar-Gurrieri C; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.
Blanco J; AIDS Research Institute, IrsiCaixa, Campus Can Ruti, 08916 Badalona, Spain.; Doctorate School, Microbiology Department, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.; Doctorate School, Medicine Department, University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Spain.; CIBERINFEC, ISCIII, 28029 Madrid, Spain.; Germans Trias I Pujol Research Institute (IGTP), Campus Can Ruti, 08916 Badalona, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 May 19; Vol. 24 (10). Date of Electronic Publication: 2023 May 19.
Typ publikacji:
Journal Article
MeSH Terms:
Vaccines, Virus-Like Particle*
HIV-1*
Mice ; Animals ; Cats ; Leukemia Virus, Feline ; Mice, Inbred C57BL ; Retroviridae ; HIV Envelope Protein gp41
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Extremely Thermostabilizing Core Mutations in Coiled-Coil Mimetic Proteins of HIV-1 gp41 Produce Diverse Effects on Target Binding but Do Not Affect Their Inhibitory Activity.
Autorzy:
Cano-Muñoz M; Departamento de Química Física, Instituto de Biotecnología, Unidad de Excelencia de Química Aplicada a Biomedicina y Medioambiente (UEQ), Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain.
Cesaro S; Departamento de Química Física, Instituto de Biotecnología, Unidad de Excelencia de Química Aplicada a Biomedicina y Medioambiente (UEQ), Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain.
Morel B; Departamento de Química Física, Instituto de Biotecnología, Unidad de Excelencia de Química Aplicada a Biomedicina y Medioambiente (UEQ), Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain.
Lucas J; INSERM U1109, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, 67084 Strasbourg, France.
Moog C; INSERM U1109, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, 67084 Strasbourg, France.
Conejero-Lara F; Departamento de Química Física, Instituto de Biotecnología, Unidad de Excelencia de Química Aplicada a Biomedicina y Medioambiente (UEQ), Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2021 Apr 12; Vol. 11 (4). Date of Electronic Publication: 2021 Apr 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Molecular Docking Simulation*
Mutation*
HIV Envelope Protein gp41/*antagonists & inhibitors
Oligopeptides/*chemistry
Anti-HIV Agents/chemistry ; Anti-HIV Agents/pharmacology ; Binding Sites ; HIV Envelope Protein gp41/chemistry ; HIV Envelope Protein gp41/genetics ; HIV Envelope Protein gp41/metabolism ; Isoleucine/genetics ; Oligopeptides/genetics ; Oligopeptides/pharmacology ; Protein Binding ; Protein Stability
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Quaternary Interaction of the HIV-1 Envelope Trimer with CD4 and Neutralizing Antibodies.
Autorzy:
Liu Q; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20852, USA.
Zhang P; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20852, USA.
Lusso P; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20852, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 Jul 20; Vol. 13 (7). Date of Electronic Publication: 2021 Jul 20.
Typ publikacji:
Journal Article; Research Support, N.I.H., Intramural; Review
MeSH Terms:
Virus Internalization*
Antibodies, Neutralizing/*metabolism
CD4 Antigens/*metabolism
HIV Antibodies/*metabolism
HIV Envelope Protein gp120/*metabolism
HIV Envelope Protein gp41/*metabolism
Binding Sites, Antibody ; Cell Line ; HIV Envelope Protein gp120/chemistry ; HIV Envelope Protein gp41/chemistry ; Humans ; Models, Molecular ; Protein Binding ; Protein Conformation ; Protein Multimerization ; Protein Structure, Quaternary/physiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane.
Autorzy:
Wang C; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27 Tai-Ping Road, Beijing 100850, China.
Li Q; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27 Tai-Ping Road, Beijing 100850, China.
Sun L; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, 131 Dong An Road, Shanghai 200032, China.
Wang X; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, 131 Dong An Road, Shanghai 200032, China.
Wang H; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27 Tai-Ping Road, Beijing 100850, China.
Zhang W; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27 Tai-Ping Road, Beijing 100850, China.
Li J; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27 Tai-Ping Road, Beijing 100850, China.; Key Laboratory of Structure-Based Drug Design and Discovery of the Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
Liu Y; Key Laboratory of Structure-Based Drug Design and Discovery of the Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
Lu L; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, 131 Dong An Road, Shanghai 200032, China.
Jiang S; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, 131 Dong An Road, Shanghai 200032, China.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Apr 23; Vol. 15 (5). Date of Electronic Publication: 2023 Apr 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV-1*/metabolism
HIV Fusion Inhibitors*/pharmacology
HIV Fusion Inhibitors*/chemistry
Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/metabolism
Humans ; HIV Envelope Protein gp41/chemistry ; Peptides/pharmacology ; Peptides/metabolism ; Glycoproteins/metabolism ; Cell Membrane/metabolism ; Receptors, CCR5/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Structure, membrane topology and influence of cholesterol of the membrane proximal region: transmembrane helical anchor sequence of gp41 from HIV.
Autorzy:
Aisenbrey C; Institut de chimie de Strasbourg, UMR7177, University of Strasbourg/CNRS, 4, Rue Blaise Pascal, 67070, Strasbourg, France.
Rifi O; Institut de chimie de Strasbourg, UMR7177, University of Strasbourg/CNRS, 4, Rue Blaise Pascal, 67070, Strasbourg, France.
Bechinger B; Institut de chimie de Strasbourg, UMR7177, University of Strasbourg/CNRS, 4, Rue Blaise Pascal, 67070, Strasbourg, France. .; Institut Universitaire de France, Paris, France. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2020 Dec 17; Vol. 10 (1), pp. 22278. Date of Electronic Publication: 2020 Dec 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cholesterol/*chemistry
HIV Envelope Protein gp41/*ultrastructure
HIV Infections/*genetics
HIV-1/*ultrastructure
Amino Acid Sequence/genetics ; HIV Envelope Protein gp41/chemistry ; HIV Envelope Protein gp41/genetics ; HIV Infections/physiopathology ; HIV Infections/virology ; HIV-1/chemistry ; Humans ; Peptides/chemistry ; Peptides/genetics ; Protein Structure, Secondary
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
Autorzy:
Geng X; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.; Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Liu Z; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.; Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Yu D; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.; Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Qin B; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Zhu Y; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.; Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Cui S; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Chong H; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. .; Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. .
He Y; NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. .; Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. .
Pokaż więcej
Źródło:
Viruses [Viruses] 2019 Jul 03; Vol. 11 (7). Date of Electronic Publication: 2019 Jul 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anti-Retroviral Agents/*pharmacology
HIV Envelope Protein gp41/*drug effects
HIV Envelope Protein gp41/*metabolism
HIV-1/*drug effects
Virus Internalization/*drug effects
Amino Acid Sequence ; HIV Envelope Protein gp41/chemistry ; HIV Envelope Protein gp41/genetics ; HIV-1/genetics ; HIV-1/physiology ; Membrane Fusion/drug effects ; Models, Molecular ; Mutagenesis, Site-Directed ; Mutation ; Peptides/chemistry ; Peptides/pharmacology ; Structure-Activity Relationship
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Neutralizing Antibodies Targeting HIV-1 gp41.
Autorzy:
Caillat C; Institut de Biologie Structurale (IBS), University Grenoble Alpes, Commissariat à L'énergie Atomique et Aux Énergies Alternatives (CEA), Centre National de la Recherche Scientifique (CNRS), 38000 Grenoble, France.
Guilligay D; Institut de Biologie Structurale (IBS), University Grenoble Alpes, Commissariat à L'énergie Atomique et Aux Énergies Alternatives (CEA), Centre National de la Recherche Scientifique (CNRS), 38000 Grenoble, France.
Sulbaran G; Institut de Biologie Structurale (IBS), University Grenoble Alpes, Commissariat à L'énergie Atomique et Aux Énergies Alternatives (CEA), Centre National de la Recherche Scientifique (CNRS), 38000 Grenoble, France.
Weissenhorn W; Institut de Biologie Structurale (IBS), University Grenoble Alpes, Commissariat à L'énergie Atomique et Aux Énergies Alternatives (CEA), Centre National de la Recherche Scientifique (CNRS), 38000 Grenoble, France.
Pokaż więcej
Źródło:
Viruses [Viruses] 2020 Oct 23; Vol. 12 (11). Date of Electronic Publication: 2020 Oct 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Antibodies, Neutralizing/*chemistry
Antibodies, Neutralizing/*immunology
HIV Antibodies/*immunology
HIV Envelope Protein gp41/*immunology
AIDS Vaccines/immunology ; Animals ; Epitopes/immunology ; HIV Envelope Protein gp41/genetics ; HIV-1/genetics ; HIV-1/immunology ; Humans ; Mice ; Mutation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting a Conserved Lysine in the Hydrophobic Pocket of HIV-1 gp41 Improves Small Molecule Antiviral Activity.
Autorzy:
He L; Department of Basic Sciences, Touro University California College of Osteopathic Medicine, 1310 Club Drive, Mare Island, Vallejo, CA 94592, USA.
Zhou G; Department of Basic Sciences, Touro University California College of Osteopathic Medicine, 1310 Club Drive, Mare Island, Vallejo, CA 94592, USA.
Sofiyev V; Department of Basic Sciences, Touro University California College of Osteopathic Medicine, 1310 Club Drive, Mare Island, Vallejo, CA 94592, USA.
Garcia E; Master of Science in Medical Health Sciences, Touro University California College of Osteopathic Medicine, 1310 Club Drive, Mare Island, Vallejo, CA 94592, USA.
Nguyen N; Master of Science in Medical Health Sciences, Touro University California College of Osteopathic Medicine, 1310 Club Drive, Mare Island, Vallejo, CA 94592, USA.
Li KH; Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, San Francisco, CA 94143, USA.
Gochin M; Department of Basic Sciences, Touro University California College of Osteopathic Medicine, 1310 Club Drive, Mare Island, Vallejo, CA 94592, USA.; Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, San Francisco, CA 94143, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Dec 02; Vol. 14 (12). Date of Electronic Publication: 2022 Dec 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
MeSH Terms:
HIV Fusion Inhibitors*/pharmacology
HIV Fusion Inhibitors*/chemistry
HIV-1*/metabolism
Humans ; Antiviral Agents/pharmacology ; Antiviral Agents/metabolism ; Lysine/metabolism ; HIV Envelope Protein gp41/chemistry ; Hydrophobic and Hydrophilic Interactions
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Molecular recognition of a membrane-anchored HIV-1 pan-neutralizing epitope.
Autorzy:
Torralba J; Instituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.; Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.
de la Arada I; Instituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.
Partida-Hanon A; Institute of Physical Chemistry 'Rocasolano' (IQFR-CSIC), Serrano 119, E-28006, Madrid, Spain.
Rujas E; Instituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.; Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.; Ikerbasque, Basque Foundation for Science, 48013, Bilbao, Spain.; Pharmacokinetic, Nanotechnology and Gene Therapy Group, Faculty of Pharmacy, University of the Basque Country UPV/EHU, 01006, Vitoria-Gasteiz, Spain.; Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, 01006, Vitoria-Gasteiz, Spain.
Arribas M; Instituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.
Insausti S; Instituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.; Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain.
Valotteau C; Laboratoire Adhesion et Inflammation, INSERM U1067, CNRS UMR 7333, Aix-Marseille Université, Turing Centre for Living systems, Marseille, France.
Valle J; Laboratory of Proteomics and Protein Chemistry, Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003, Barcelona, Spain.
Andreu D; Laboratory of Proteomics and Protein Chemistry, Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003, Barcelona, Spain.
Caaveiro JMM; Laboratory of Global Healthcare, School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 819-0395, Japan.
Jiménez MA; Institute of Physical Chemistry 'Rocasolano' (IQFR-CSIC), Serrano 119, E-28006, Madrid, Spain.
Apellániz B; Department of Physiology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad, 7, 01006, Vitoria-Gasteiz, Spain. .
Redondo-Morata L; Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017/CIIL-Centre d'Infection et d'Immunité de Lille, F-59000, Lille, France. .
Nieva JL; Instituto Biofisika (CSIC-UPV/EHU), University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain. .; Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), PO Box 644, 48080, Bilbao, Spain. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2022 Nov 18; Vol. 5 (1), pp. 1265. Date of Electronic Publication: 2022 Nov 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV-1*/chemistry
HIV Envelope Protein gp41/chemistry ; HIV Envelope Protein gp41/metabolism ; HIV Antibodies/chemistry ; Epitopes ; Lipid Bilayers/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein.
Autorzy:
Joshi VR; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.; Department of Virology, Harvard Medical School, Boston, Massachusetts, United States of America.
Newman RM; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Pack ML; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Power KA; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Munro JB; Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Okawa K; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Madani N; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Sodroski JG; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.; Department of Microbiology, Harvard Medical School, Boston, Massachusetts, United States of America.
Schmidt AG; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.; Department of Microbiology, Harvard Medical School, Boston, Massachusetts, United States of America.
Allen TM; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2020 May 11; Vol. 16 (5), pp. e1008577. Date of Electronic Publication: 2020 May 11 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Envelope Protein gp41*/antagonists & inhibitors
HIV Envelope Protein gp41*/immunology
Antibodies, Neutralizing/*pharmacology
HIV Antibodies/*pharmacology
HIV Infections/*immunology
HIV-1/*immunology
Virus Internalization/*drug effects
Antibodies, Neutralizing/immunology ; CD4 Antigens/immunology ; HEK293 Cells ; HIV Antibodies/immunology ; HIV Infections/drug therapy ; HIV Infections/pathology ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates.
Autorzy:
Cottrell CA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, California, United States of America.
van Schooten J; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Bowman CA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Yuan M; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Oyen D; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Shin M; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Morpurgo R; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
van der Woude P; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
van Breemen M; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Torres JL; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Patel R; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Gross J; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Sewall LM; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Copps J; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Ozorowski G; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, California, United States of America.
Nogal B; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, California, United States of America.
Sok D; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, California, United States of America.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Rakasz EG; Wisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin, United States of America.
Labranche C; Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.
Vigdorovich V; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America.
Christley S; Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, Texas, United States of America.
Carnathan DG; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, California, United States of America.; Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Sather DN; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America.
Montefiori D; Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Silvestri G; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, California, United States of America.; Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Burton DR; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, California, United States of America.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.; The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, United States of America.
Moore JP; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America.
Wilson IA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, California, United States of America.; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Sanders RW; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, United States of America.
Ward AB; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, California, United States of America.
van Gils MJ; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2020 Aug 31; Vol. 16 (8), pp. e1008753. Date of Electronic Publication: 2020 Aug 31 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Epitope Mapping*
AIDS Vaccines/*immunology
Epitopes/*immunology
HIV Antibodies/*immunology
HIV Envelope Protein gp120/*immunology
HIV Envelope Protein gp41/*immunology
HIV-1/*immunology
AIDS Vaccines/genetics ; Animals ; Antibodies, Monoclonal, Murine-Derived/immunology ; Epitopes/genetics ; HIV Antibodies/genetics ; HIV Envelope Protein gp41/genetics ; HIV-1/genetics ; Macaca mulatta ; Protein Multimerization/genetics ; Protein Multimerization/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identification of variant HIV envelope proteins with enhanced affinities for precursors to anti-gp41 broadly neutralizing antibodies.
Autorzy:
Zhu H; Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, United States of America.
Mathew E; Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, United States of America.
Connelly SM; Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, United States of America.
Zuber J; Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, United States of America.
Sullivan M; Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, United States of America.
Piepenbrink MS; Infectious Diseases Division, University of Rochester Medical Center, Rochester, NY United States of America.
Kobie JJ; Infectious Diseases Division, University of Rochester Medical Center, Rochester, NY United States of America.
Dumont ME; Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2019 Sep 10; Vol. 14 (9), pp. e0221550. Date of Electronic Publication: 2019 Sep 10 (Print Publication: 2019).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibody Affinity*
Mutation*
Antibodies, Neutralizing/*immunology
HIV Envelope Protein gp41/*immunology
Protein Precursors/*immunology
Antibodies, Viral/immunology ; Epitopes/chemistry ; Epitopes/genetics ; Epitopes/immunology ; HIV Envelope Protein gp41/chemistry ; HIV Envelope Protein gp41/genetics ; Protein Binding ; Protein Precursors/chemistry ; Protein Precursors/genetics ; Protein Stability
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Natural-Based Antitumor Compound T21 Decreases Survivin Levels through Potent STAT3 Inhibition in Lung Cancer Models.
Autorzy:
Martínez-García D; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, 08905 Barcelona, Spain.; Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Pérez-Hernández M; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, 08905 Barcelona, Spain.; Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Korrodi-Gregório L; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, 08905 Barcelona, Spain.
Quesada R; Department of Chemistry, Universidad de Burgos, 09001 Burgos, Spain.
Ramos R; Department of Thoracic Surgery and University of Barcelona, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Baixeras N; Department of Pathology, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Pérez-Tomás R; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, 08905 Barcelona, Spain.; Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Soto-Cerrato V; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, 08905 Barcelona, Spain. .; Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. .
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2019 Aug 13; Vol. 9 (8). Date of Electronic Publication: 2019 Aug 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Biological Products/*pharmacology
Carcinoma, Non-Small-Cell Lung/*drug therapy
HIV Envelope Protein gp41/*pharmacology
Lung Neoplasms/*drug therapy
Peptide Fragments/*pharmacology
STAT3 Transcription Factor/*antagonists & inhibitors
Survivin/*antagonists & inhibitors
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Biological Products/chemical synthesis ; Biological Products/chemistry ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Cells, Cultured ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; HIV Envelope Protein gp41/chemical synthesis ; HIV Envelope Protein gp41/chemistry ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Molecular Structure ; Peptide Fragments/chemical synthesis ; Peptide Fragments/chemistry ; STAT3 Transcription Factor/metabolism ; Structure-Activity Relationship ; Survivin/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 2154

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies